VANCOUVER, British Columbia,
May 5, 2015 /PRNewswire/
-- InMed Pharmaceuticals Inc. ("InMed") (CSE: IN;
OTCQB: IMLFF), a clinical stage biopharmaceutical company that
specializes in developing safer, more effective cannabis-based
therapies, announced today that former GW Pharmaceuticals
financier, investor, and Non-Executive Director, Peter Mountford, has agreed to support InMed as
Strategic Advisor with primary responsibility for the European
markets.
In this role, Mr. Mountford will leverage his previous success
in the emerging field of cannabinoid biotech, providing capital
markets counsel and advisory for InMed, as well as enhancing
shareholder value by advising the Company on European financing
opportunities. As a financier, early stage investor, and
Non-Executive Director for GW Pharmaceuticals, Mr. Mountford was
successful in assisting the company with raising a substantial
level of funds for the successful development of its business and
was instrumental in its 2001 initial public offering
(IPO).
Peter Mountford commented, "I am
attracted to InMed's growing therapeutic pipeline and accelerated
development strategy, as well as the impressive team of executives
and advisors that the company has assembled. Their cutting-edge
approach of therapy identification and development based on their
proprietary platform technology is particularly compelling.
As the market for cannabinoid-based therapeutics continues to
expand globally, I look forward to supporting InMed with the
expectation that my significant experience investing directly and
securing investments in this sector will result in enhanced
visibility for the company among European investors."
Craig Schneider, President and
CEO of InMed, remarked "Aligning InMed with Peter Mountford brings another highly
influential leader in cannabinoid based therapy development to our
company. Specifically, we look forward to benefitting from
Peter's proven financing capabilities and deep knowledge of
European investors as we seek to expand InMed's shareholder base
and attract new capital."
Mr. Mountford is currently a Non-Executive Director of RWS
Holdings plc, one of the world's leading patent translation and
search companies, and one of the top 50 companies on AIM, the
London Stock Exchange's highly successful market for smaller
growing companies. Mr. Mountford was instrumental in the IPO
of RWS in 2003, and since then its share price has grown more than
six times. More recently, Mr. Mountford was one of the founders of
Learning Technologies Group plc, Europe's leading e-learning company, whose
share price has risen almost four times since its successful IPO in
2013. Mr. Mountford has invested in and helped many companies
raise large amounts of capital from Private Equity funds, pre-IPO
investors, and Institutional Investors (through IPOs and reversals
into cash shells). He is highly experienced in all areas of
corporate finance including fund-raising, acquisitions, disposals,
MBOs, MBIs and flotations.
About InMed
InMed is a clinical stage
biopharmaceutical company that specializes in developing
cannabis-based therapies through the research and development into
the extensive pharmacology of cannabinoids coupled with innovative
drug delivery systems. InMed's proprietary platform technology,
product pipeline and accelerated development pathway are the
fundamental value drivers of the company.
For more information, please visit our website at
www.inmedpharma.com
Contact:
InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
Tel: 604.669.7207
Chris Bogart
VP
Corporate Development
Tel: 604.669.7207
info@inmedpharma.com
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
(Investors)
jdrumm@tiberend.com
212-375-2664
Amy Wheeler (Media)
awheeler@tiberend.com
646-362-5750
Forward-Looking Information
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities
laws. Forward-looking information is based on management's
current expectations and beliefs and is subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about Peter
Mountford supporting InMed as a financial advisor for the
European markets; Mr. Mountford enhancing shareholder value and
Company visibility by introducing the Company to key European
investors; expanding InMed's shareholder base and attracting new
capital; and the fundamental value drivers of the company.
With respect to the forward-looking information contained in this
news release, InMed has made numerous assumptions regarding, among
other things: the continued availability of Mr. Mountford; the
effectiveness of Mr. Mountford in reaching European investors; and
continued economic and market stability. While InMed considers
these assumptions to be reasonable, these assumptions are
inherently subject to significant business, economic, competitive,
market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could
cause InMed's actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
information contained herein. Known risk factors include,
among others: Mr. Mountford may become unavailable; Mr. Mountford's
efforts to bring in valuable European investors may not be as
successful as anticipated, or at all; InMed's proprietary platform
technology, product pipeline and accelerated development pathway
may not return their expected level of value; and economic or
market conditions may worsen.
A more complete discussion of the risks and uncertainties facing
InMed is disclosed in InMed's continuous disclosure filings with
Canadian securities regulatory authorities at www.sedar.com. All
forward-looking information herein is qualified in its entirety by
this cautionary statement, and InMed disclaims any obligation to
revise or update any such forward-looking information or to
publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/inmed-engages-peter-mountford-as-strategic-advisor-300077158.html
SOURCE InMed Pharmaceuticals, Inc.